Solaris-pharma.com Listed by everest Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On January 21, 2025, the ransomware group known as everest listed Solaris-pharma.com on its leak site, claiming responsibility for a ransomware attack that involved the exfiltration of internal files and the full publication of that data. The number of people affected remains unknown, and public details about the incident are limited to the group's listing and the reported summary of full data publication. This matters because Solaris-pharma.com operates in the pharmaceutical sector, where internal files can include sensitive operational, research, and personal information whose exposure carries lasting risks for individuals and the organisation alike.

What is known so far comes solely from the everest listing and associated reporting; no independent confirmation of the scale, method, or exact contents has been made public. The claim of full data publication indicates the group asserts it has released the material it says it took, but verification of that release and its precise nature is not available in the public record.

What happened

According to the reported facts, Solaris-pharma.com was listed by the everest ransomware group on January 21, 2025. The listing describes a ransomware attack in which internal files were allegedly exfiltrated, followed by full data publication. No further specifics—such as the date the intrusion began, how access was obtained, the volume of data taken, or any ransom demand—have been disclosed. The number of people affected is unknown. Public detail is limited to the group's claim of the listing and the summary that the data was fully published. There is no confirmed information on whether the organisation has acknowledged the incident, contained it, or notified regulators or individuals.

Who is everest?

Everest is a ransomware group that has operated for several years using a double-extortion model: encrypting systems while also stealing data and threatening to publish it if a ransom is not paid. The group maintains a leak site where it lists victims and, in many cases, posts samples or full archives of claimed stolen material. Its tactics typically include initial access through phishing, compromised credentials, or exploitation of remote services, followed by lateral movement, data theft, and deployment of ransomware. Everest has previously claimed attacks against organisations across multiple sectors, often publicising the listings to increase pressure. In this case, the listing of Solaris-pharma.com is treated as an unverified claim by the group; the facts do not confirm independent validation of the intrusion or the published data.

Solaris-pharma.com and its sector

Solaris-pharma.com is an organisation operating under a pharmaceutical-related domain, placing it within the broader pharmaceutical and life-sciences sector. Companies in this sector typically manage research data, manufacturing and supply-chain records, regulatory filings, employee information, and sometimes customer or patient-related details. Even when patient health data is not the primary focus, internal files often contain proprietary formulas, clinical trial materials, vendor contracts, financial records, and personally identifiable information of staff and partners. A breach involving such an organisation is consequential because the sector is heavily regulated, relies on trust in data integrity, and frequently holds information that competitors, criminals, or other adversaries could misuse. Exposure can disrupt operations, invite regulatory scrutiny, and create long-term risks for anyone whose details appear in the files.

What was likely exposed

The facts state that internal files were exfiltrated in a ransomware attack and that full data publication was reported. No specific data types beyond “internal files” are named, and the exact contents remain unconfirmed. Organisations of this kind commonly hold employee records (names, contact details, payroll and HR documents), internal correspondence, research and development materials, supplier and partner contracts, financial documents, and operational systems data. It is possible that some of these categories were among the files claimed by everest, but that has not been verified. Public detail does not identify any particular documents, databases, or personal information fields as confirmed exposed. Readers should treat any assumption about precise contents as speculative until further official disclosure occurs.

Why it matters

For individuals whose information may have been among the internal files, the real-world risks include identity theft, targeted phishing, and social-engineering attempts that exploit knowledge of employment, projects, or personal details. Even limited personal data can be combined with other breaches to enable fraud. For the organisation, the consequences can include operational disruption, loss of intellectual property, regulatory investigations, contractual liabilities with partners, and reputational damage that affects ongoing research or commercial relationships. Because the group claims full publication, any sensitive material that was taken may now circulate beyond the original attackers, increasing the chance of secondary misuse. The absence of confirmed numbers of affected people or exact data types does not reduce the need for caution; it simply means the full scope is still unknown.

If your data was in this claimed breach

If you have a past or present connection to Solaris-pharma.com—as an employee, contractor, partner, or customer—treat the possibility of exposure seriously even though the precise contents are unconfirmed. Monitor financial accounts and credit reports for unusual activity, enable multi-factor authentication on important accounts, and be alert for phishing messages that reference the company or your role. Change passwords for any accounts that may have reused credentials linked to work email. Consider placing fraud alerts with credit bureaus if you believe personal identifiers were involved. Readers can also run a free exposure scan of their email address to check whether their information has already surfaced in known breach data sets. Stay informed through official channels from the organisation rather than relying solely on third-party claims, and report any suspected misuse to the appropriate authorities.

AICompiled with AI assistance from public sources and published under our editorial standards.